Welcome to CSNpharm! For Research Use Only!
Guanylate Cyclase
| Cat. No. | Product Name | CAS No. | Information |
|---|---|---|---|
| CSN19707 | Vericiguat | 1350653-20-1 | Vericiguat targets soluble guanylate cyclase sGC and is used for treating heart failure |
| CSN15708 | Riociguat | 625115-55-1 | Riociguat acts as stimulator of soluble guanylate cyclase sGC that is used to treat ipulmonary hypertension |
| CSN25656 | Praliciguat | 1628730-49-3 | Praliciguat is a novel, orally available sGC stimulator. It suppresses stellate cell fibrotic transformation and inhibits fibrosis and inflammation in models of NASH. |
| CSN25839 | ODQ | 41443-28-1 | ODQ is a selective and irreversible inhibitor of nitric oxide-sensitive guanylyl cyclase. |
| CSN26373 | NS-2028 | 204326-43-2 | NS-2028 is a potent soluble guanylyl cyclase (sGC) inhibitor with Ki of 8 nM. NS-2028 inhibits sGC activity in homogenates of mouse cerebellum and neuronal NO synthase with IC50 values of 17 nM and 20 nM[1]. NS-2028 is commonly used in the research of nitric oxide signaling pathways, it inhibits NO-dependent relaxant responses in non-vascular smooth muscle completely (1 μM)[1]. NS-2028 reduces vascular endothelial growth factor-induced angiogenesis and permeability[2]. |
| CSN12227 | Lificiguat | 170632-47-0 | Lificiguat is an acivator of guanylyl cyclase sGC and can bind to the heme-containing domain of the subunit with Kd of 06 M - 11 M |
| CSN18217 | Cinaciguat | 329773-35-5 | Cinaciguat is the first of a class of soluble guanylate cyclase sGC activators in clinical development for acute decompensated heart failure |
| CSN15709 | BAY 41-2272 | 256376-24-6 | BAY 41-2272 is an activator of guanylate cyclases (sGC). |
+1-708-781-1677
+1-708-286-6026
sales@csnpharm.com
